Susumé
Continuously blocks the transmission of bacteria
Contributing to infectious disease prevention with solid evidence
We aim to contribute to society through specialized infection control measures.
June 1, 2026 Updated
TSUKASA SAKURADA
The spread of infectious diseases has occurred many times in the past.
There is a history of many fatalities.
It is difficult to solve and is considered an eternal challenge for humanity.
Many infectious diseases occur in poor living conditions.
My experience working on a JICA project in the past has
This is a big turning point.
Infectious diseases are transmitted through the air, droplets, and contact.
It is generally believed that approximately 80% of infections are caused by contact with bacteria and viruses.
Therefore, if transmission can be blocked continuously, significant reductions can be achieved.
The newly developed antibacterial agent is a solid antibacterial agent, unlike conventional agents.
Long-lasting and non-toxic
It is characterized by the fact that it does not leach and therefore has no environmental impact.
There are many possible applications for this technology in the future, including food hygiene management, water, and air.
This new company will focus on infectious disease prevention.
In addition, the business model will be a licensing business.
It goes without saying that companies must always have a social mission.
We aim to work with licensees to promote employment for the elderly and regional development.
access
Susumé Co., Ltd
Address
09-00-39 Shirakabadaira Mitsuinomori Tateshinakogen, Chino, Nagano 391-0213 JAPAN
CEO
Tsukasa Sakurada
contact
Latest News
◎ September 6, 2025
Continuous Antimicrobial Technology "AbedulAg+" for Infection Prevention
～Scientific Validation and Exploration of Technical Possibilities～
How to Confront Infections Caused by Drug-Resistant Bacteria?
Please enter from "How to Combat Infections Caused by Drug-Resistant Bacteria?"
at the top of the homepage. You can view the details there.
Table of Contents
1, Why did we choose textiles as a commercial product?
2, Why do we focus on drug-resistant bacteria in infectious diseases?
3, Understanding the current status of infections caused by drug-resistant bacteria (Japan-US comparison)
a) Severity b) Current status of nosocomial infections c) Drug-resistant bacteria to be aware of d) Policy comparison
4, Why are infectious diseases said to be humanity's eternal challenge?
5, In 2008, the U.S. EPA approved copper alloys as continuous antimicrobial agents for the first time in the world.
(Posted on November 19, 2025)
a) Proposed physical contact disinfection rather than pharmaceutical administration.
b) Clinically demonstrated effectiveness against multidrug-resistant bacteria such as MRSA and VRE.
6, Reasons for Using Silver Ions as Active Species (Posted January 20, 2026)
7, Challenges of Conventional Silver-based Antimicrobial Agents and New Proposals (Posted January 21, 2026)
8, Advantages of the silver ion disinfection mechanism (posted March 7, 2026)
9, Advantages of Silver Ion Disinfection in the Medical Field (Submitted on March 11, 2026)
10, Absolute Advantages of Silver Ion Disinfection in Terms of Safety (Submitted on March 11, 2026)
11, Superiority of silver ion sterilization in terms of environmental safety (Posted March 13, 2026)
12, Economic Advantages of Silver Ion Antimicrobial Technology (Posted March 15, 2026)
13, Technical Advantages of the Electrolytic Silver Ion Long-Lasting Antimicrobial Agent “AbedulAg⁺” (Posted on
March 20, 2026)
14, Fourteen years ago, copper alloys were approved by the U.S. Environmental Protection Agency (EPA)
as persistent antimicrobial materials. Subsequently, the world’s first clinical trial demonstrated that
infection prevention could be achieved with a statistically significant probability of 58%, leading to the
publication of numerous academic papers. However, despite these promising results, practical
implementation has stagnated. In this study, we examine the underlying reasons for this limited
adoption by comparing copper-based systems with our newly developed persistent antimicrobial agent,
“AbedulAg⁺.” (Posted on March 21, 2026)
15. Strategic importance of sustained-release fungicides (Posted March 31, 2026)
16. The importance of research on infectious diseases (Posted April 19, 2026)
17. Application Landscape of Interface-Mediated, Non-Leaching Antimicrobial Platform (Posted on May
9, 2026)
18. Economic Impact of the Durable Antimicrobial Technology "AbedulAg+" (Posted on June 18, 2026)
.png){kind=small}